Ann: Non-Executive Director retirement, page-37

Maybe it’s just me. Nextellis sales in 1H23 were
a disaster even compared to 2H22. Then 2H23
we have a surge in sales mainly due to S and M
Am I right in believing that this product continues
to require consultation from reps to maintain market
share. It appears to me the product itself is not of
sufficIent quality and advantage over competitors
to maintain repeat business. Surely we just throwing
good money after bad buying sales at a continual
financial loss just to keep 145 reps in jobs .CEO
mentioned sales conference ( I think in Florida . I’m
too angry to remember ) . I have personally attended
these type of extremely expensive exercises. In Orlando
a couple of times. Some of the most memorable fun
all expenses paid time of my life. They cost millions $$$
$$. Shawn then states this as a reason sales declined
during this period. For Gods Sake can’t our pharmaceutical products at least keep selling without
having them rammed down someone’s throat. How good
mare Maynes medication?